文献速递贫血与红细胞疾病血栓与止血

SLFN14:遗传性血小板减少症中巨核细胞与血小板的神秘调控因子

SLFN14: An Elusive Regulator of Megakaryocytes and Platelets in Inherited Thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2026-10-26

本文综述了SLFN14基因在遗传性血小板减少症中的作用,该基因致病变异主要导致出血倾向而无其他系统症状。SLFN14可能作为内切核糖核酸酶和干扰素诱导的抗病毒效应因子,属于Schlafen先天免疫RNA调控家族。文章总结了其结构、表达、酶活性及在血小板生成中的角色,并探讨致病变异如何破坏这些过程。

要点

  • SLFN14致病变异引起遗传性血小板减少症,主要表现为出血倾向。
  • SLFN14可能作为内切核糖核酸酶和抗病毒效应因子发挥功能。
  • SLFN14属于Schlafen家族,参与RNA调控和血小板生成。

核心结论

  • SLFN14是遗传性血小板减少症的致病基因之一,其致病变异主要导致出血倾向而无其他系统症状。
  • SLFN14可能作为内切核糖核酸酶和干扰素诱导的抗病毒效应因子,属于Schlafen先天免疫RNA调控家族。

研究设计与样本

  • 综述:通过PubMed检索“SLFN14”,自2010年首次报道以来仅32篇相关文献。
  • 综合当前关于SLFN14的结构特征、表达谱、酶活性及在血小板生成中作用的知识。

主要发现

  • SLFN14致病变异导致遗传性血小板减少症,主要与出血倾向相关,无其他系统症状证据。
  • SLFN14可能作为内切核糖核酸酶和干扰素诱导的抗病毒效应因子,限制病毒进入后复制。
  • SLFN14属于Schlafen先天免疫RNA调控家族,参与RNA调控。

关键数值与推荐

  • 遗传性血小板减少症定义为循环血小板持续减少(< 150 × 10^9/L),临床严重程度可变。
  • 截至报道,44个基因的致病变异与遗传性血小板减少症相关。

临床怎么用

  • SLFN14致病变异应纳入遗传性血小板减少症的基因诊断考虑。
  • 识别SLFN14变异有助于准确诊断、患者管理和靶向治疗开发。

局限性

  • 文献数量有限(仅32篇),SLFN14在巨核细胞和血小板中的调控机制尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inherited thrombocytopenias (ITs) are a heterogeneous group of bleeding disorders characterized by a persistent reduction in circulating platelets (< 150 × 109/L) and variable clinical severity. To date, pathogenic variants in 44 genes have been linked to inherited thrombocytopenia, and defining these underlying genetic causes remains essential for accurate diagnosis, patient management, and the development of targeted therapies. The gene for Schlafen Family Member 14 (SLFN14) is among the more recently discovered genes, and pathogenic variants in SLFN14 cause inherited thrombocytopenia, primarily associated with bleeding tendencies but without evidence for other systemic symptoms. Remarkably, by searching 'SLFN14' in PubMed, only 32 publications have appeared since the first report about this gene in 2010. These studies suggest that SLFN14 may function as an endoribonuclease and also act as an interferon-inducible antiviral effector that restricts viruses post-entry, placing it within the broader Schlafen innate immune RNA-regulation family. With this review, we aim to synthesize current knowledge on SLFN14, highlighting its structural features, expression profile, enzymatic activities, and role in platelet biogenesis, while examining how pathogenic variants disrupt these processes. We also discuss emerging evidence of its antiviral function and broader implications for RNA regulation, providing a framework to guide future research.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Tran M, Labarque V, Freson K, et al. SLFN14: An Elusive Regulator of Megakaryocytes and Platelets in Inherited Thrombocytopenia. J Thromb Haemost. 2026. PMID: 42933657. doi:10.1016/j.jtha.2026.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。